Dr. Robert Langer Becomes Part of Klotho Neurosciences’ Vision
Klotho Neurosciences, Inc. (NASDAQ: KLTO) recently announced that Dr. Robert Langer, a notable figure in biotechnology and co-founder of Moderna, has joined its Scientific Advisory Board. This addition is a major step for Klotho Neurosciences as it seeks to enhance its strategic initiatives in the field of neurodegenerative disorders.
A Leader in Biotechnology
Dr. Langer's reputation as a leading scientist and innovator precedes him. His contributions to drug delivery technologies and tissue engineering have earned him prestigious accolades, including the National Medal of Science. As a key player in Moderna’s groundbreaking development of mRNA therapeutics, he significantly impacted the biotech industry, particularly with the COVID-19 vaccine. Currently, he holds a professorship at the Massachusetts Institute of Technology (MIT) along with a role in the Harvard–MIT Program in Health Sciences and Technology.
Targeting Neurodegenerative Diseases
Klotho Neurosciences focuses on advancing therapies aimed at critical unmet medical needs in neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s. The company utilizes research surrounding Klotho protein, identified for its neuroprotective properties and capacity for promoting longevity. This platform has already attracted patents globally, protecting its innovative approach.
Growth and Development Under New Guidance
Dr. Joseph Sinkule, Chairman and CEO of Klotho Neurosciences, expressed excitement about Dr. Langer's involvement, highlighting the value his experience brings to the team. Sinkule reminisced about their previous collaboration, reinforcing the collaborative spirit within Klotho Neurosciences. With Dr. Langer’s insights, the company is optimistic about advancing its therapy pipeline.
Potential Impact in the Biotech Sector
As a new member of the Scientific Advisory Board, Dr. Langer's role will involve guiding scientific and clinical development for Klotho's product candidates. The company stands at a dynamic point in biotech, focusing on solutions for daunting challenges presented by neurodegenerative diseases. His participation marks a pivotal moment in their journey to engineer transformative therapies based on the proprietary s-KL technology platform.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is dedicated to the development of groundbreaking, disease-modifying technologies specifically targeting conditions affecting the brain and central nervous system. The firm possesses exclusive rights to innovative technologies that aim to treat various age-related disorders, including ALS, Alzheimer’s, Parkinson’s, and more. Their current initiatives include proprietary gene therapy programs utilizing DNA and RNA, with valuable assets in clinical-stage antibody biologics targeting cancer and autoimmune diseases.
Contact Information
For inquiries, reach out to:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Frequently Asked Questions
What is the role of Dr. Robert Langer at Klotho Neurosciences?
Dr. Langer joins as a member of the Scientific Advisory Board to guide scientific and clinical development.
What is Klotho Neurosciences focused on?
The company develops therapies targeting neurodegenerative diseases like ALS and Alzheimer’s, leveraging the Klotho protein.
Why is Dr. Langer's involvement significant?
His expertise in biotechnology and drug delivery will greatly benefit Klotho’s research and development efforts.
What technologies does Klotho Neurosciences utilize?
Klotho uses patented gene and protein therapies, as well as advanced drug delivery systems.
How can investors learn more about Klotho Neurosciences?
Investors can reach out via email or visit their website for more information on the company's initiatives.
